Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Semiconductors, Circuits & Optics
48 pending office actions • 29 clients • 47 examiners • 24 art units • 0 of 48 (0%) have an AI response strategy ready
Junhe Law Office P.C. focuses on Biotechnology & Pharmaceuticals. It has 1239 career applications. The firm has a resolved allowance rate of 90.41 percent. It averages 3.67 office actions per allowance. There are 32 pending office actions.
The 90.41 percent allowance rate is based on 1239 career applications. The average of 3.67 office actions per allowance indicates the typical prosecution path for an allowance. The 32 pending office actions represent the firm's current workload in the biotechnology sector.
Based on the USPTO statutory response window for each pending office action. 7 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 7 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 4 (8%) |
| §103 only | 8 (17%) |
| §102 only | 1 (2%) |
| §112 only | 6 (12%) |
| Double-patenting only | 1 (2%) |
| Double-patenting + other | 7 (15%) |
| Multi-statute (no §101) | 21 (44%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MALSAWMA, LALRINFAMKIM HMAR | 2 | 90.5% | +8.8% |
| KORTMAN, CURTIS JAMES | 1 | 79.4% | +24.0% |
| FAIRCHILD, MALLIKA DIPAYAN | 1 | 79.4% | +18.4% |
| TIWARI, VYOMA SHUBHAM | 1 | 31.5% | +48.1% |
| KONOPELSKI SNAVEL, SARA ELIZABETH | 1 | 33.3% | +38.9% |
| ROBINSON, HOPE A | 1 | 67.7% | +43.1% |
| JOHNSON, CHRISTOPHER A | 1 | 84.4% | +8.2% |
| STARK, JARRETT J | 1 | 70.5% | +11.5% |
| NELSON, MATTHEW M | 1 | 57.9% | +23.9% |
| PROSSER, ALISSA J | 1 | 15.7% | +11.2% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18605841 | INTEGRATED PACKAGE AND METHOD FOR MAKING THE SAME | MALSAWMA, LALRINFAMKIM HMAR | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16918958 | HIGH CAPACITY MOLECULE DETECTION | POHNERT, STEVEN C | 202d overdue |
| 19218586 | MEMORY SYSTEM, COMPUTER SYSTEM AND DATA INTERACTION METHOD | KORTMAN, CURTIS JAMES | — |
| 18730790 | TRUNCATED FORMS OF IGA PROTEASE, FUSION PROTEINS COMPRISING A TRUNCATED FORM OF IGA PROTEASE AND USES THEREOF | ROBINSON, HOPE A | — |
| 18765338 | METHODS FOR FORMING CONDUCTIVE STRUCTURES BETWEEN TWO SUBSTRATES | JOHNSON, CHRISTOPHER A | — |
| 18749657 | SEMICONDUCTOR PACAKGE AND METHOD FOR FORMING THE SAME | STARK, JARRETT J | — |
| 18749572 | DENTAL APPLIANCE SYSTEM AND AN ORTHODONTIC METHOD USING THE SAME | NELSON, MATTHEW M | — |
| 18741818 | COMPOSITION FOR PURIFICATION OF BIOFLUIDS | PROSSER, ALISSA J | — |
| 18740630 | SEMICONDUCTOR PACKAGES WITH MULTIPLE TYPES OF CONDUCTIVE COMPONENTS | SENGDARA, VONGSAVANH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19218586 | MEMORY SYSTEM, COMPUTER SYSTEM AND DATA INTERACTION METHOD | KORTMAN, CURTIS JAMES | — |
| 18869848 | IMPLANTABLE HEART FAILURE TREATMENT DEVICE | FAIRCHILD, MALLIKA DIPAYAN | — |
| 18838613 | PEPTIDES FOR DISSOLVING PROTEIN AGGREGATES AND METHODS THEREOF | TIWARI, VYOMA SHUBHAM | — |
| 18836758 | METHODS FOR TREATING CATARACTS USING POLYPEPTIDES | KONOPELSKI SNAVEL, SARA ELIZABETH | — |
| 18730790 | TRUNCATED FORMS OF IGA PROTEASE, FUSION PROTEINS COMPRISING A TRUNCATED FORM OF IGA PROTEASE AND USES THEREOF | ROBINSON, HOPE A | — |
| 18749657 | SEMICONDUCTOR PACAKGE AND METHOD FOR FORMING THE SAME | STARK, JARRETT J | — |
| 18749572 | DENTAL APPLIANCE SYSTEM AND AN ORTHODONTIC METHOD USING THE SAME | NELSON, MATTHEW M | — |
| 18741818 | COMPOSITION FOR PURIFICATION OF BIOFLUIDS | PROSSER, ALISSA J | — |
| Art Unit | Apps |
|---|---|
| 1624 | 2 |
| 2892 | 2 |
| 1675 | 2 |
| 1644 | 2 |
| 1643 | 2 |
| 3772 | 1 |
| 1619 | 1 |
| 2818 | 1 |
| 2812 | 1 |
| 2813 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19218586 | MEMORY SYSTEM, COMPUTER SYSTEM AND DATA INTERACTION METHOD | Montage Technology (Kunshan) Co., Ltd. | KORTMAN, CURTIS JAMES | §103§112 | Non-Final OA | — | Pending | May 26, 2025 | |
| 18869848 | IMPLANTABLE HEART FAILURE TREATMENT DEVICE | UNITED INNOMED (SHANGHAI) LIMITED | FAIRCHILD, MALLIKA DIPAYAN | §112 | Non-Final OA | — | Pending | Nov 27, 2024 | |
| 18838613 | PEPTIDES FOR DISSOLVING PROTEIN AGGREGATES AND METHODS THEREOF | Rejukon Biopharm Inc. | TIWARI, VYOMA SHUBHAM | §102§112DP | Non-Final OA | — | Pending | Aug 15, 2024 | |
| 18836758 | METHODS FOR TREATING CATARACTS USING POLYPEPTIDES | Rejukon Biopharm Inc. | KONOPELSKI SNAVEL, SARA ELIZABETH | §102§103§112DP | Non-Final OA | — | Pending | Aug 08, 2024 | |
| 18730790 | TRUNCATED FORMS OF IGA PROTEASE, FUSION PROTEINS COMPRISING A TRUNCATED FORM OF IGA PROTEASE AND USES THEREOF | Shanghai Alezyme Pharmaceuticals Ltd. | ROBINSON, HOPE A | §103§112 | Non-Final OA | — | Pending | Jul 22, 2024 | |
| 18765338 | METHODS FOR FORMING CONDUCTIVE STRUCTURES BETWEEN TWO SUBSTRATES | Stats Chippac Pte. Ltd. | JOHNSON, CHRISTOPHER A | §103§112 | Non-Final OA | — | Pending | Jul 08, 2024 | |
| 18749657 | SEMICONDUCTOR PACAKGE AND METHOD FOR FORMING THE SAME | Stats Chippac Pte. Ltd. | STARK, JARRETT J | §103§112 | Non-Final OA | — | Pending | Jun 21, 2024 | |
| 18749572 | DENTAL APPLIANCE SYSTEM AND AN ORTHODONTIC METHOD USING THE SAME | Wuxi Ea Medical Instruments Technologies Limited | NELSON, MATTHEW M | 3772 | §101§102 | Final Rejection | — | Pending | Jun 20, 2024 |
| 18741818 | COMPOSITION FOR PURIFICATION OF BIOFLUIDS | Beacon Medcare (Hk) Limited | PROSSER, ALISSA J | 1619 | §103§112Other | Non-Final OA | — | Pending | Jun 13, 2024 |
| 18740630 | SEMICONDUCTOR PACKAGES WITH MULTIPLE TYPES OF CONDUCTIVE COMPONENTS | Stats Chippac Pte. Ltd. | SENGDARA, VONGSAVANH | §102§103 | Non-Final OA | — | Pending | Jun 12, 2024 | |
| 18673384 | SENSOR PACKAGE AND A METHOD FOR FORMING THE SAME | Stats Chippac Pte. Ltd. | RAMOS FELICIANO, ELISEO | §102§103 | Non-Final OA | — | Pending | May 24, 2024 | |
| 18670747 | SEMICONDUCTOR PACKAGE WITH IMPROVED HEAT DISSIPATION | Jcet Stats Chippac Korea Limited | WIEGAND, TYLER J | §102§112 | Non-Final OA | — | Pending | May 22, 2024 | |
| 18709820 | COMPOUND FOR REDUCING URIC ACID LEVELS | Newsoara Biopharma Co., Ltd. | BRAUN, MADELINE E | §103§112 | Final Rejection | — | Pending | May 14, 2024 | |
| 18655254 | ELECTRONIC PACKAGE AND A PACKAGING METHOD | Stats Chippac Pte. Ltd. | HARBOTTLE, CHARLOTTE ELIZABETH | §103§112 | Non-Final OA | — | Pending | May 04, 2024 | |
| 18646903 | SEMICONDUCTOR DEVICE AND METHOD FOR MAKING THE SAME | Stats Chippac Pte. Ltd. | THROCKMORTON, ROBERT EMIL | 2818 | §102§103 | Non-Final OA | — | Pending | Apr 26, 2024 |
| 18646867 | SENSOR PACKAGE AND METHOD FOR FORMING THE SAME | Stats Chippac Pte. Ltd. | RIRIE, EVERETT TRAJAN | §103§112 | Non-Final OA | — | Pending | Apr 26, 2024 | |
| 18639994 | SEMICONDUCTOR DEVICE WITH A PARTIAL SHIELDING LAYER AND A METHOD FOR MAKING THE SAME | Jcet Stats Chippac Korea Limited | MUNOZ, ANDRES F | §103 | Final Rejection | — | Pending | Apr 19, 2024 | |
| 18638733 | SEMICONDUCTOR DEVICE AND A METHOD FOR FORMING A SEMICONDUCTOR DEVICE | Stats Chippac Pte. Ltd. | TRAN, DZUNG | §103 | Non-Final OA | — | Pending | Apr 18, 2024 | |
| 18636301 | SEMICONDUCTOR PACKAGE STRIP AND METHOD FOR FORMING A SEMICONDUCTOR DEVICE | Jcet Stats Chippac Korea Limited | TURNER, BRIAN | §102§103 | Final Rejection | — | Pending | Apr 16, 2024 | |
| 18700268 | METHODS FOR DEVELOPING A CELL LINE FOR PRODUCING VIRUS IN SUSPENSION CELL CULTURE | Porton Advanced Solutions Ltd. | KIM, TAEYOON | §103§112 | Non-Final OA | — | Pending | Apr 10, 2024 | |
| 18697015 | HALOGENATED PHENYLARSINE OXIDE COMPOUND AND APPLICATION THEREOF | Nuo-Beta Pharmaceutical Technology (Shanghai) Co., Ltd. | HABTE, KAHSAY | 1624 | §102§112DP | Non-Final OA | — | Pending | Mar 29, 2024 |
| 18605842 | PARTIALLY SHIELDED SEMICONDUCTOR DEVICE AND METHOD FOR MAKING THE SAME | Stats Chippac Pte. Ltd. | MALSAWMA, LALRINFAMKIM HMAR | 2892 | §102§103 | Non-Final OA | — | Pending | Mar 15, 2024 |
| 18605841 | INTEGRATED PACKAGE AND METHOD FOR MAKING THE SAME | Stats Chippac Pte. Ltd. | MALSAWMA, LALRINFAMKIM HMAR | 2892 | §103 | Non-Final OA | — | Pending | Mar 15, 2024 |
| 18597878 | SEMICONDUCTOR DEVICE WITH IMPROVED HEAT DISSIPATION AND METHOD FOR MAKING THE SAME | Jcet Stats Chippac Korea Limited | MAZUMDER, DIDARUL A | 2812 | §103 | Final Rejection | — | Pending | Mar 06, 2024 |
| 18292922 | NOVEL ANTI-SIRPA ANTIBODIES | Elpiscience Biopharma, Ltd. | LANDSMAN, ROBERT S | §112 | Non-Final OA | — | Pending | Jan 28, 2024 | |
| 18414500 | SEMICONDUCTOR DEVICE AND METHOD FOR MAKING THE SAME | Stats Chippac Pte. Ltd. | AHMED, SHAHED | 2813 | §102§103 | Non-Final OA | — | Pending | Jan 17, 2024 |
| 18395626 | SEMICONDUCTOR DEVICE AND METHOD FOR MAKING THE SAME | Stats Chippac Pte. Ltd. | NGUYEN, SOPHIA T | 2893 | §103§112 | Final Rejection | — | Pending | Dec 25, 2023 |
| 18556665 | HETERODIMERIC ANTIBODIES AND ANTIGEN-BINDING FRAGMENT THEREOF | Chimagen Biosciences, Ltd. | CUNNINGCHEN, KATHLEEN MARY | 1646 | §102§103§112 | Non-Final OA | — | Pending | Oct 21, 2023 |
| 18555341 | NOVEL ANTI-HVEGFR2 ANTIBODIES | Suzhou Transcenta Therapeutics Co., Ltd. | BALLARD, KIMBERLY | 1675 | §112 | Non-Final OA | — | Pending | Oct 13, 2023 |
| 18549928 | METHOD OF TREATING DISEASES USING GREMLIN1 ANTAGONISTS | Suzhou Transcenta Therapeutics Co., Ltd. | BELYAVSKYI, MICHAIL A | 1644 | §103DP | Final Rejection | — | Pending | Sep 11, 2023 |
| 18546980 | ANTI-CLDN18.2 ANTIBODY CONJUGATES | BEIJING CANCER HOSPITAL | DUNN, LINDSAY MICHELLE | 1644 | §102§103§112DP | Non-Final OA | — | Pending | Aug 18, 2023 |
| 18447315 | SEMICONDUCTOR DEVICES WITH PYRAMIDAL SHIELDING AND METHOD FOR MAKING THE SAME | Stats Chippac Pte. Ltd. | BULLARD-CONNOR, GENEVIEVE GRACE | 2899 | §103 | Final Rejection | 9d | Pending | Aug 10, 2023 |
| 18264765 | METHODS OF MODULATING ANDROGEN RECEPTOR CONDENSATES | Etern Therapeutics (Wuxi) Co., Ltd. | BELL, SARA ELIZABETH | 1625 | §102§103§112 | Non-Final OA | — | Pending | Aug 09, 2023 |
| 18264764 | METHODS FOR MODULATING A SRC-1 CONDENSATE | Etern Therapeutics Inc. | BERKE-SCHLESSEL, DAVID W | 1651 | §101§102§103§112 | Non-Final OA | — | Pending | Aug 09, 2023 |
| 18263088 | APPARATUS AND SYSTEMS FOR MONITORING AND TREATING CATARACTS | Edinburgh Biosciences Ltd. | FABIAN JR, ROBERTO | 2877 | §103 | Non-Final OA | 33d | Pending | Jul 26, 2023 |
| 18338313 | NOVEL METHOD FOR PRODUCING ANTIBODIES | Tsinghua University | NATARAJAN, MEERA | 1643 | §103 | Non-Final OA | — | Pending | Jun 20, 2023 |
| 18254606 | NOVEL CONJUGATE MOLECULES TARGETING CD39 AND TGFBETA | Elpiscience Biopharma, Ltd. | HADDAD, MAHER M | 1641 | §102 | Final Rejection | — | Pending | May 26, 2023 |
| 18246516 | NOVEL ANTI-CLAUDIN18 ANTIBODIES | Elpiscience Biopharma, Ltd. | BERHANE, SELAM | 1675 | §112 | Final Rejection | 62d | Pending | Mar 24, 2023 |
| 18172322 | METHODS FOR DETECTING HOMOLOGOUS RECOMBINATION DEFICIENCY IN CANCER PATIENTS | Genegeniedx Corp. | HAYES, JONATHAN EDWARD | §101§103§112 | Non-Final OA | — | Pending | Feb 22, 2023 | |
| 18005356 | DRUG DELIVERY SYSTEM FOR LOCALLY DELIVERING THERAPEUTIC AGENTS AND USES THEREOF | Coval Biopharma (Shanghai) Co., Ltd. | BRANDSEN, BENJAMIN MICHAEL | 1693 | §103§112Other | Final Rejection | — | Pending | Jan 13, 2023 |
| 18066275 | PYRAZINE COMPOUNDS AND USES THEREOF | Dizal (Jiangsu) Pharmaceutical Co., Ltd. | WILLIS, DOUGLAS M | 1624 | §112Other | Final Rejection | 55d | Pending | Dec 14, 2022 |
| 18056242 | TASK PROCESSING METHOD AND APPARATUS USED IN MULTI-TANK SCENARIO | Montage Technology Co., Ltd. | GHAFFARI, ABU Z | 2195 | §101§103 | Final Rejection | — | Pending | Nov 16, 2022 |
| 18050476 | METHODS FOR SCREENING VARIANT OF TARGET GENE | Applied Stemcell, Inc. | BOESEN, CHRISTIAN C | 1684 | DP | Final Rejection | — | Pending | Oct 28, 2022 |
| 17918557 | NOVEL MEDICAL USE OF MDM2 INHIBITORS | Ascentage Pharma Group Corp Limited | NOLAN, JASON MICHAEL | 1600 | §103DP | Final Rejection | — | Pending | Oct 12, 2022 |
| 17885578 | ERBB RECEPTOR INHIBITORS | Dizal (Jiangsu) Pharmaceutical Co., Ltd. | HIRAKIS, SOPHIA P | 1623 | §112 | Non-Final OA | 23d overdue | Pending | Aug 11, 2022 |
| 17761602 | ATOMIZER | Suzhou Skywell Healthcare Information Co., Ltd. | LEBRON DE JESUS, GRACIELA NATALIA | 3785 | §103 | Final Rejection | — | Pending | Mar 18, 2022 |
| 17636373 | NOVEL ANTI-CLDN18.2 ANTIBODIES | Transcenta Therapeutics, Inc. | SHUPE, ELIZABETH A | 1643 | §112DPOther | Non-Final OA | 71d | Pending | Feb 18, 2022 |
| 16918958 | HIGH CAPACITY MOLECULE DETECTION | Davinci Bio, Inc. | POHNERT, STEVEN C | 1683 | §102§103§112 | Final Rejection | 202d overdue | Pending | Jul 01, 2020 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial